VACCINES AGAINST HELMINTH INFECTIONS. (PARAVAC)
The aim is:
1) Development and delivery of vaccines against the parasites of livestock of high economic and/or public health importance specifically gastrointestinal nematodes, lungworms, liver fluke, and Echinococcus granulosus.
2) Characterisation of Protective Immune Responses to these parasites to inform vaccine delivery.
3) Knowledge exchange and training of scientists and veterinarians in participating developing countries in the characterisation of immune responses, vaccine technology and application.
4) Outreach to farming organisations and other stakeholder groups in both developed and developing participating countries with a view to paving the way for early adopters of new vaccine technology.
1) Development and delivery of vaccines against the parasites of livestock of high economic and/or public health importance specifically gastrointestinal nematodes, lungworms, liver fluke, and Echinococcus granulosus.
2) Characterisation of Protective Immune Responses to these parasites to inform vaccine delivery.
3) Knowledge exchange and training of scientists and veterinarians in participating developing countries in the characterisation of immune responses, vaccine technology and application.
4) Outreach to farming organisations and other stakeholder groups in both developed and developing participating countries with a view to paving the way for early adopters of new vaccine technology.
1.- Coordination project training programme.
2.- Housed vaccine trials against F. hepatica in sheep.
3.- Pathological studies of fields vaccine trials against F. hepatica conducted by other partners.
WP1.1 Recombinant and native proteins required to conduct vaccine trials for O. ostertagi, C. oncophora, H. contortus, F. hepatica, D. viviparus and E. granulosus (all by 30 months).
WP1.2 Glycan definition on selected protective antigens (12 and 48 months).
WP1.3 Production of Bacillus subtilis (living) delivery system for E. granulosus antigens (18 months).
WP2.1 Refined definition of the precise immunological effectors of vaccine-induced immunity (throughout).
WP2.2 The nature of antibody binding required to stimulate protection (18 months).
WP2.3 Definition of the differences arising in the initiation of the immune response in the presence of different adjuvants (12 months).
WP2.4 Microarray definition of the immediate response to vaccination following intramuscular injection with different adjuvants. (24 months)
WP2.5 Provision of a rational base for adjuvant selection for vaccine delivery. (throughout)
WP2.6 To develop E. granulosus vaccine delivery using B. subtilis spores and nanoparticle technology. (24 months)
WP2.7 Studies with T. hydatigena to verify the impact of the most promising vaccine prototype on the reproductive organs of worms. (36 months)
WP2.8 An increased understanding of the host-parasite relationship between fluke and their definitive host which will inform and enhance the efficacy of vaccination programmes. (36 months)
WP2.9 An understanding of whether fluke increases susceptibility of infected cattle to other infections normally controlled by a pro-inflammatory response. (36 months)
WP3.1 Prototype O. ostertagi vaccine comprising either single or combinations of the 3 recombinant OPA proteins. (30 months)
WP3.2 Prototype O. ostertagi L4 gut antigen vaccine. (36 months)
WP3.3 Prototype C. oncophora vaccine comprising purified native ES proteins. (30 months)
WP3.4 Effective Haemonchus native adult gut protein vaccine for use in sheep, goats and cattle. (36 months)
WP3.5 Proof of principle of the utility of C. elegans for the production of efficacious nematodes protein vaccines. (30 months)
WP3.6 Improved recombinant cathepsin L-based vaccines for the control of F. hepatica infection in cattle (33 months)
WP4.1 Information on basic host-parasite interactions in naturally infected cattle (36 months)
WP4.2 Model to describe the efficacy of a vaccine and duration of protection required to reduce (a) disease and (b) transmission within a herd.(36 months).
WP4.3 A cost benefit analysis of the implementation of a vaccine programme (48 months).
WP4.4 Efficacy and safety of the new vaccine in the natural host under field conditions (48 months).
WP4.5 Completion of a detailed plan for transitioning a lead antigen (vaccine) to proof of concept (30 months).
WP5.1 Progression of the project as indicated in the GANTT chart outlining milestone progression during the lifetime of the project.
WP5.2 Execution of training plans.
WP5.3 Development and maintenance of project web-site.
Livestock production efficiency is impaired by worm infections which are ubiquitous in cattle, sheep and goats world-wide. These cause severely debilitating gastro-intestinal, respiratory or liver disorders, dependent on the infecting species. Control of these parasites relies almost exclusively on the use of drugs, a solution threatened by the global emergence of worm strains which are no longer affected by these chemicals. An alternative, greener and more sustainable approach is to control these infestations by vaccination, but, with one exception, there are no commercial vaccines available for any of these parasites.
INMUNOPATOLOGÍA DE ANIMALES DOMÉSTICOS, SILVESTRES Y EXÓTICOS.
Code PAIDI: AGR262
José Pérez Arévalo. partner.
Universidad de Córdoba
Budget of Andalusian group: € 983,350.00
- Universidad de Córdoba